Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6

Documenti analoghi

• Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS‐CoV‐2: AGILE CST‐3a/b
  di: B. Thompson, et al.
  Pubblicazione: (2025)
• Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐CoV‐2 infection
  di: E. Challenger, et al.
  Pubblicazione: (2025)
• Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration
  Pubblicazione: (2024)
• Pharmacokinetics of long‐acting cabotegravir and rilpivirine in seminal plasma throughout the dosing interval
  di: N. Neverette, et al.
  Pubblicazione: (2025)
• Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19
  Pubblicazione: (2024)